Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Restructuring Costs (2023 - 2025)

Maravai Lifesciences Holdings (MRVI) has 3 years of Restructuring Costs data on record, last reported at $10.4 million in Q4 2025.

  • For Q4 2025, Restructuring Costs rose 173916.67% year-over-year to $10.4 million; the TTM value through Dec 2025 reached $17.8 million, up 1568.45%, while the annual FY2025 figure was $17.8 million, 1568.45% up from the prior year.
  • Restructuring Costs reached $10.4 million in Q4 2025 per MRVI's latest filing, up from $7.4 million in the prior quarter.
  • Across five years, Restructuring Costs topped out at $10.4 million in Q4 2025 and bottomed at -$1.2 million in Q1 2024.
  • Average Restructuring Costs over 3 years is $3.3 million, with a median of $6000.0 recorded in 2024.
  • Peak YoY movement for Restructuring Costs: crashed 99.91% in 2024, then surged 184750.0% in 2025.
  • A 3-year view of Restructuring Costs shows it stood at $6.5 million in 2023, then plummeted by 99.91% to $6000.0 in 2024, then skyrocketed by 173916.67% to $10.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Restructuring Costs were $10.4 million in Q4 2025, $7.4 million in Q3 2025, and $6000.0 in Q4 2024.